Valproate add-on therapy for drug-resistant focal epilepsy (original) (raw)
Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy VIPe-study. A multicenter observational open-label study
Hassan Al Hail
Saudi medical journal, 2007
View PDFchevron_right
IV Valproate in generalized convulsive status epilepticus: a systematic review
Luigi Bongiovanni, Francesco Brigo
European Journal of Neurology, 2012
View PDFchevron_right
Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics
Rosa Arteaga, Javier Adín
European Journal of Clinical Pharmacology, 2006
View PDFchevron_right
Efficacy and safety of intravenous valproate for status epilepticus: a systematic review
Francesco Brigo
2014
View PDFchevron_right
Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy (VIPe-study)
Boulenouar Mesraoua
2007
View PDFchevron_right
Efficacy of Valproate in Partial Epilepsy and Patient Compliance and Satisfaction with Long Acting Valproate Form
Seher Naz
journalagent.com
View PDFchevron_right
Comparison of short-term efficacy of valproate sustained-release between adult and children as first-line monotherapy in management of partial epilepsy: A multicenter observational open-label study
Mohiuddin Sikder
Journal of National Institute of Neurosciences Bangladesh, 2015
View PDFchevron_right
Valproate in children with newly diagnosed idiopathic generalized epilepsy
George Vartzelis
Acta Neurologica Scandinavica, 2010
View PDFchevron_right
Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults
Leif Gjerstad
Acta Neurologica Scandinavica, 2007
View PDFchevron_right
Assessment of the reporting quality of RCTs for sodium valproate in status epilepticus pupublished from 2007 to 2018 based on the CONSORT statement
Ιωάννης ΛιΆμπας
2020
View PDFchevron_right
Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy
Gus Baker
Epilepsy & Behavior, 2003
View PDFchevron_right
A comparative study of progabide, valproate, and placebo as add-on therapy in patients with refractory epilepsy
Patricia Crawford
Journal of Neurology, Neurosurgery & Psychiatry, 1986
View PDFchevron_right
Accuracy of Calculated Free Valproate Levels in Adult Patients With Status Epilepticus
Stephan Rueegg
Neurology, 2020
View PDFchevron_right
Valproate-induced Parkinsonism in epilepsy patients
Danrick Jamora
Movement disorders : official journal of the Movement Disorder Society, 2007
View PDFchevron_right
Valproate in the treatment of epilepsy in women and girls Recommendations from a joint Task Force of ILAE-Commission on European Affairs and European Academy of Neurology (EAN)
Maria Paola Canevini
Epilepsia, 2015
View PDFchevron_right
Prospective Observational Study of Sodium Valproate in Seizure Control and Associated Adverse Drug Reactions in Pediatric Population
nagesh adla
2015
View PDFchevron_right
Antiepileptic drug add-on therapy for focal epilepsy: a network meta-analysis
Myrsini Gianatsi
Cochrane Database of Systematic Reviews, 2021
View PDFchevron_right
Conventional and controlled release valproate in children with epilepsy: a cross-over study comparing plasma levels and cognitive performances
T. Stijnen
Epilepsy Research, 1992
View PDFchevron_right
Reduction of Steady-State Valproate Levels by Other Antiepileptic Drugs
J. Chris Sackellares
Epilepsia, 1981
View PDFchevron_right
Common reference-based indirect comparison meta-analysis of intravenous valproate versus intravenous phenobarbitone in generalized convulsive status epilepticus
Luigi Bongiovanni, Frediano Tezzon, Stanley Igwe, Francesco Brigo
Journal of the Neurological Sciences, 2013
View PDFchevron_right
Low-dose sodium valproate in the treatment of idiopathic generalized epilepsies
J. Salas-Puig
Acta Neurologica Scandinavica, 2013
View PDFchevron_right
The Frequency of Reversible Parkinsonism and Cognitive Decline Associated with Valproate Treatment: A Study of 364 Patients with Different Types of Epilepsy
Nikola Vojvodic
Epilepsia, 2006
View PDFchevron_right
The tolerability and safety of valproate sodium injection given as an intravenous infusion
R Eugene Ramsay
Journal of Epilepsy, 1997
View PDFchevron_right
Role of valproate across the ages. Treatment of epilepsy in the elderly
Bettina Schmitz
Acta Neurologica Scandinavica, 2006
View PDFchevron_right
New valproate regulations, informed choice and seizure risk
heather angus-leppan
Journal of neurology, 2024
View PDFchevron_right
Conversion from delayed-release sodium valproate to extended-release sodium valproate: Initial results and long-term follow-up
Erik Lehman
Epilepsy & Behavior, 2006
View PDFchevron_right
Valproic Acid as Adjuvant Treatment for Convulsive Status Epilepticus: a Randomised Clinical Trial
Christine Lebert
View PDFchevron_right
Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus
James Dalton
Annals of Pharmacotherapy, 1999
View PDFchevron_right
Comparative bioavailaibilty of two valproic acid delayed-release tablets in healthy volunteers with tighter acceptance criteria to anticipate breakthrough seizures
Yahdiana Harahap
Pharmaceutical Sciences Asia
View PDFchevron_right
Disposition of sodium valproate in epileptic patients
Stefano Calzetti
British Journal of Clinical Pharmacology, 1978
View PDFchevron_right
Safety of intravenous valproate
John Pellock
Annals of Neurology, 1995
View PDFchevron_right
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial
Paola Nicolaides
The Lancet, 2007
View PDFchevron_right